Roche's Genentech unit will dish out $150 million upfront to Adaptimmune to develop and commercialize allogeneic cell therapies for up to five shared cancer targets, the companies said Tuesday. The deal also includes personalized allogeneic T-cell therapies. Specific oncology indications were kept under the hood. Source: Fierce Biotech 7/9/2021